Geron (FRA:GON) Operating Margin %: -0.45% (As of Mar. 2026)


FRA:GON Geron Corp FRA:GON
39 GF Score
Price €1.21
GF Value €5.55
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Geron Operating Margin %?

Geron FRA:GON +1.47% 39 Operating Margin % is -0.45% as of Mar. 2026. GuruFocus rates FRA:GON with a GF Score™ of 39/100 and a GF Value™ of €5.55 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 944 Biotechnology companies, Geron ranks better than 64.09% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Geron's Operating Income for the three months ended in Mar. 2026 was €-0.2 Mil. Geron's Revenue for the three months ended in Mar. 2026 was €44.8 Mil. Therefore, Geron's Operating Margin % for the quarter that ended in Mar. 2026 was -0.45%.

Good Sign:

Geron Corp operating margin is expanding. Margin expansion is usually a good sign.

The historical rank and industry rank for Geron's Operating Margin % or its related term are showing as below:

FRA:GON' s Operating Margin % Range Over the Past 10 Years
Min: -81832.91   Med: -5549.31   Max: -17.89
Current: -17.89


FRA:GON's Operating Margin % is ranked better than
64.09% of 944 companies
in the Biotechnology industry
Industry Median: -86.83 vs FRA:GON: -17.89

Geron's 5-Year Average Operating Margin % Growth Rate was 71.90% per year.

Geron's Operating Income for the three months ended in Mar. 2026 was €-0.2 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was €-30.1 Mil.


Geron  (FRA:GON) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Geron Operating Margin % Related Terms


Geron Operating Margin % Historical Data

* Premium members only.

The historical data trend for Geron's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Geron Operating Margin % Chart

Geron Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8,182.40 -23,231.08 -81,957.14 -225.64 -28.04

Geron Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -42.18 -25.40 -29.41 -17.72 -0.45

FRA:GON vs LBRX, ODTX, OMER: Operating Margin % Comparison

For the Biotechnology subindustry, Geron's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Geron Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Geron's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Geron's Operating Margin % falls into.


FRA:GON
39GF Score
Geron Corp FRA:GON
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Geron Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Geron's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=-44.026 / 157.034
=-28.04 %

Geron's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=-0.204 / 44.839
=-0.45 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of -0.45% mean?
Geron (FRA:GON) has a Operating Margin % of -0.45% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Geron and its competitors. According to the industry distribution chart, Geron ranks #339 out of 944 companies in the Biotechnology industry, placing it in the top 35.9%.
Is Geron's Operating Margin % too high?
Geron's current Operating Margin % is -0.45%. Based on the distribution chart, Geron ranks #339 out of 944 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Geron has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Geron's Operating Margin % compare to LBRX and ODTX?
According to the Biotechnology industry distribution chart, Geron ranks #339 out of 944 companies for Operating Margin %. This puts Geron in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Geron and its competitors. Geron's current Operating Margin % is -0.45%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Geron stock overvalued right now?
Based on GuruFocus' analysis, Geron (FRA:GON) is currently considered Possible Value Trap. The stock's GF Value™ is €5.55, compared to a current price of €1.21 — trading 78.2% below its estimated fair value. The current Operating Margin % is -0.45%. Geron's overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Geron (FRA:GON), the current Operating Margin % is -0.45% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Geron (FRA:GON) Overvalued in 2026?

Based on GuruFocus' analysis, Geron stock appears to be undervalued. The current stock price of €1.21 is trading 78.2% below its estimated GF Value™ of €5.55. GuruFocus considers Geron to be Possible Value Trap.

Key valuation signals for FRA:GON:

  • Operating Margin %: -0.45%
  • GF Value™: €5.55 vs. price of €1.21 (78.2% below fair value)
  • GF Score™: 39/100 with 4 warning signs

No single metric tells the full story. See the FRA:GON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Geron Business Description

Address 919 East Hillsdale Boulevard, Suite 250, Foster City, CA, USA, 94404
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
39GF Score

Get the complete analysis for FRA:GON

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.21
Price
€5.55
GF Value